CD22-directed CAR T-cell therapy for large B-cell lymphomas progressing after CD19-directed CAR T-cell therapy: a dose-finding phase 1 study
Authors: Matthew J Frank, John H Baird, Anne Marijn Kramer, Hrishikesh K Srinagesh, Shabnum Patel, Annie Kathleen Brown, Jean S Oak, Sheren F Younes, Yasodha Natkunam, Mark P Hamilton, Yi-Jiun Su, Neha Agarwal, Harshini Chinnasamy, Emily Egeler, Sharon Mavroukakis, Steven A Feldman, Bita Sahaf, Crystal L Mackall, Lori Muffly, David B Miklos, Dorota Danuta Klysz, Nikolaos Gkitsas-Long, Juliana Bacigalupi, Maria Iglesias, Emma Crawford, Linnea Nichols, Kristen Cunanan, John Tamaresis, Jay Y. Spiegel, Zachary Ehlinger, Adam Kuo, Warren D. Reynolds, Sally Arai, Laura Johnston, Robert Lowsky, Everett Meyer, Robert S. Negrin, Andrew R. Rezvani, Parveen Shiraz, Surbhi Sidana, Wen Kai Weng, Sushma Bharadwaj, Saurabh Dahiya, Melody Smith, Liora M. Schultz, Sneha Ramakrishna, Kara L. Davis, Ramya Tunuguntla
Journal: The Lancet (2024)

BackgroundOutcomes are poor for patients with large B-cell lymphoma who relapse after CD19-directed chimeric antigen receptor (CAR) T-cell therapy (CAR19). CD22 is a nearly universally expressed B-cell surface antigen and the efficacy of a CD22-directed CAR T-cell therapy (CAR22) in large B-cell lymphoma is unknown, which was what we aimed to examine in this study.MethodsIn this single centre, open-label, dose-escalation phase 1 trial, we intravenously administered CAR22 at two dose levels (1 million and 3 million CAR22-positive T cells per kg of bodyweight) to adult patients (aged ≥18 years) who relapsed after CAR19 or had CD19-negative large B-cell lymphoma. The primary endpoints were manufacturing feasibility, safety measured by the incidence and severity of adverse events and dose-limiting toxicities, and identification of the maximum tolerated dose (ie, the recommended phase 2 dose). This study is registered with ClinicalTrials.gov (NCT04088890) and is active, but closed for enrolment.FindingsFrom Oct 17, 2019, to Oct 19, 2022, a total of 41 patients were assessed for eligibility; however, one patient withdrew. 40 patients underwent leukapheresis and 38 (95%) had CAR T-cell products manufactured successfully. The median age was 65 years (range 25–84), 17 (45%) were women, 32 (84%) had elevated pretreatment lactate dehydrogenase, 11 (29%) had refractory disease to all previous therapies, and patients had received a median of four lines of previous therapy (range 3–8). Of the 38 patients treated, 37 (97%) had relapsed after previous CAR19. The identified maximum tolerated dose was 1 million CAR T cells per kg. Of 29 patients who received the maximum tolerated dose, no patients developed a dose-limiting toxicity or grade 3 or higher cytokine release syndrome, immune effector cell-associated neurotoxicity syndrome, or immune effector cell-associated haemophagocytic lymphohistiocytosis-like syndrome.InterpretationThis trial identifies CD22 as an immunotherapeutic target in large B-cell lymphoma and demonstrates the durable clinical activity of CAR22 in patients with disease progression after CAR19 therapy. Although these findings are promising, it is essential to recognise that this is a phase 1 dose-finding study. Further investigations are warranted to establish the long-term efficacy and to delineate the patient subgroups that will derive the most benefit from this therapeutic approach.FundingNational Cancer Institute, National Institutes of Health, Stanford Cancer Institute, Leukemia & Lymphoma Society, Parker Institute for Cancer Immunotherapy, Lymph & Co, and the European Hematology Association.